Pharmacoeconomics and Outcome Research in China
Shanlian Hu. MD. MSc. Professor
School of Public Health
Fudan University
ISPOR 2nd Asia-Pacific Conference
March 6, 2006

Total Health & Pharmaceutical Expenditure in China

Total Health & Pharmaceutical Expenditure per Capita in China

The Issues of Pharmaceutical Expenditure in China
• High proportion of pharmaceutical expenditure in total health expenditure (44.1%)
• Drug revenue is the main source of reimbursement for hospitals
• High economic burden of patients is caused by drugs
• Irrational price setting on drugs

Pharmacoeconomics Research Required by Drug Policies
• Reducing drug price 17 times in China
• Decentralization of drug price setting policy based on regional distribution
• Helping formulation of EDL and drug reimbursement list in health insurance
• Classified management of prescription drug and OTC drug since 2006

Development of Pharmacoeconomics in China
• Pharmacoeconomics has been studied in China more than ten years
• PE is a newly developed discipline in China
• Different researchers with different background have different views on PE
• PE research findings have been applying in the field of drug pricing, formulary setting, rational use of drugs
Publication of Pharmacoeconomics in China

• There were 506 pharmacoeconomics papers & 2034 pharmacoepidemiology papers published in 169 journals in 1993-2002
• The top ranking three journals are:
  -- China Pharmacy
  -- Journal of Pharmacoepidemiology
  -- Journal of Pharmacy Practice

Evaluation of PE References in China

Sample Size in KAP Survey of Pharmacoeconomics

Results of Survey

• The understanding rate of Pharmacoeconomic evaluation guideline was very low
• Lack of knowledge limited the development of Pharmacoeconomics
• The number of related studies is not enough
• The biggest hurdle of applying Pharmacoeconomics is to transfer the research results to concrete policy suggestion

Future Direction

• To disseminate theory & knowledge of Pharmacoeconomics
• To formulate PE guideline in China
• ISPOR Asia Consortium has been established
• Developing China MDA-PE & Chapter is underway